Invivyd (IVVD) Current Leases (2022 - 2026)
Invivyd's (IVVD) quarterly Current Leases came in at $1.6 million in Q2 2026, up 46.91% on a YoY basis from $1.1 million in Q2 2025, and up 22.98% quarter-over-quarter from $1.3 million in Q4 2025.
Analysis
Invivyd (IVVD) Current Leases (2022 - 2026) Analysis & Trends
Invivyd (IVVD) has reported Current Leases for 5 consecutive years, with $1.6 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Current Leases rose 46.91% year-over-year to $1.6 million; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (up 46.91% YoY), and the FY2025 full-year result was $1.3 million, up 0.77% from the prior year.
- Current Leases climbed to $1.6 million in Q2 2026 per IVVD's latest filing, from $1.3 million in the prior quarter.
- Across five years, Current Leases topped out at $1.6 million in Q3 2023 and bottomed at $315000.0 in Q1 2022.
- Historically, Current Leases has averaged $1.2 million across 5 years, with a median of $1.3 million in 2024.
- The sharpest annual moves came in 2023 and 2024: Current Leases surged 403.17% in 2023, then slumped 56.55% in 2024.
- Over 5 years, Current Leases stood at $1.6 million in 2022, then retreated by 7.44% to $1.4 million in 2023, then slipped by 9.63% to $1.3 million in 2024, then gained by 0.77% to $1.3 million in 2025, then rose by 22.98% to $1.6 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $1.6 million, $1.3 million, and $1.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 720.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 11.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | 1.62 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 1.10 Mn |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 900,000.00 |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.41 Mn |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 1.13 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Sep 30, 2023 | 1.64 Mn |
| Jun 30, 2023 | 1.61 Mn |
| Mar 31, 2023 | 1.59 Mn |
| Dec 31, 2022 | 1.56 Mn |
| Sep 30, 2022 | 329,000.00 |
| Jun 30, 2022 | 969,000.00 |
| Mar 31, 2022 | 315,000.00 |